Homocyst(e)ine, atherosclerosis, and thrombosis

Southern Medical Journal

Volumn 92, Issue 9, 1999, Pages 858-865

  Alpert, Martin A ^a,b  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH ALABAMA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; PYRIDOXINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; ENDOTHELIUM INJURY; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; LIPID PEROXIDATION; ORAL DRUG ADMINISTRATION; THROMBOSIS; VITAMIN SUPPLEMENTATION;

EID: 0032847526     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199909000-00002     Document Type: Article

References (70)

1. McCully KS: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128
2. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998; 338:1042-1050
3. Berger P: Homocysteine and coronary artery disease. ACC Educational Highlights 1998; 13:1-5
4. Carey MC, Donovan DE, FitzGerald O, et al: Homocystinuria. I. A clinical and pathological study of nine subjects in six families. Am J Med 1968; 45:7-25
5. Mudd SH, Skovby F, Levy HL, et al: The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985; 37:1-31
6. Mudd SH, Levy HL, Skovby F: Disorders of transsulfuration. The Metabolic Basis of Inherited Disease. Scriver CS, Beaudet AL, Sly WL, et al (eds). New York, McGraw-Hill Books, 1989, pp 693-734
7. Kang SS, Zhon J, Wong PWK, et al: Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43:414-421
8. Stabler SP, Marcell PD, Podell ER, et al: Evaluation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988; 81:466-474
9. Kang SS, Wong PWK, Norusis M: Homocysteinemia due to folate deficiency. Metabolism 1987; 36:458-462
10. Cuetormsen AB, Scheede J, Fiskerstrand T, et al: Plasma concentrations of homocysteine and other amniothiol compounds are related to food intake in healthy human subjects. J Nutr 1994; 124:1934-1941
11. 6 status on homocysteine metabolism. J Clin Invest 1996; 98:174-184
12. 12 deficiency than in heterozygosity for homocystinuria due to cystathionine β-synthase deficiency. Metabolism 1998; 37:175-178
13. Wilcken DE, Gupta VJ: Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979; 9:301-307
14. Moustapha A, Naso A, Nahlawi M, et al: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97:138-141
15. Chauveau P, Chudefaux B, Coydé M, et al: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 1993; 41:S72-S77
16. Egerton W, Silberberg J, Crooks R, et al: Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol 1996; 77:759-761
17. Lindgren A, Brattström L, Norrving B, et al: Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995; 26:795-800
18. 6 nutrition status and cigarette smoking. Am J Clin Nutr 1990; 51:1058-1061
19. Ueland PM, Refsum H, Stable SP, et al: Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39:1764-1779
20. Jacobsen DW, Gatautis VJ, Green R, et al: Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994; 40:873-881
21. Stampfer MJ, Malinow MR, Willett W, et al: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US Physicians. JAMA 1992; 268:877-881
22. Arnesen E, Refsum H, Bonaa KH, et al: Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24:704-709
23. Kannel WB, Castelli WP, Gordon T: Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham study. Ann Intern Med 1979; 90:85-91
24. Nygard O, Nordrehaug JE, Refsum H, et al: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230-236
25. Boushey CJ, Beresford SA, Omenn GS, et al: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-1057
26. Kang SS, Wong PW, Susmano A, et al: Thermolabile methylenetetrahydrofolic acid reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48:536-545
27. Wald NJ, Watt HC, Law MR, et al: Homocystine and ischemic heart disease. Arch Intern Med 1998; 158:862-867
28. Clarke R, Daly L, Robinson K, et al: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149-1155
29. Selhub J, Jacques PF, Bostom AG, et al: Plasma homocysteine and extracranial carotid stenosis in the Framingham Heart study. N Engl J Med 1995; 332:286-291
30. Malinow MR, Nieto FJ, Szklo M, et al: Carotid artery intimal-medical wall thickening and plasma homocyst(e)ine in asymptomatic adults: the Atherosclerosis Risk in Communities Study. Circulation 1993; 87:1107-1113
31. Perry IJ, Refsum H, Morris RW, et al: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346:1395-1398
32. Boers GHJ, Smals AGH, Trijbels FJM, et al: Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313:709-715
33. Taylor LMJr, DeFrang RD, Harris EJ Jr, et al: The association of elevated plasma homocyst(eine) with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991; 13:128-136
34. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for vascular disease - the European Concerted Action Project. JAMA 1997; 277:1775-1781
35. Bots ML, Launer LJ, Lindemars J, et al: Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. the Rotterdam study. Arch Intern Med 1999; 159:38-43
36. den Heijer M, Kostor T, Blom HJ, et al: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759-762
37. Rodgers GM, Kane WH: Activation of endogenous factor V Leiden by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77:1909-1916
38. Ridker PM, Hennekens CH, Selhub J, et al: Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95:1777-1782
39. Alfthan G, Pekkanen J, Jauhiainen M, et al: Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106:9-19
40. Folsom AR, Nieto OF, McGovern PG, et al: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms and B vitamins. the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98:204-210
41. Loscalzo J: The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98:5-7
42. Starkebaum G, Harlan JM: Endothelial cell injury due to topper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77:1370-1376
43. Misra HP: Generation of superoxide free radical during the autooxidation of thiols. J Biol Chem 1974; 249:2151-2125
44. Blom HJ, Kleinveld HA, Boers GH, et al: Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 1995; 25:149-154
45. Chin JH, Azhar S, Hoffman BB: Interactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89:10-18
46. McCully KS: Chemical pathology of homocysteine. I. Atherogenesis. Ann Clin Lab Sci 1993; 23:477-493
47. McCully KS: Homocysteine and vascular disease. Nat Med 1996; 2:386-389
48. Harker LA, Ross R, Slichter SJ, et al: Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58:731-741
49. Wall RT, Harlan JM, Harker LA, et al: Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18:113-121
50. Harker LA, Slichter SJ, Scott CR, et al: Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974; 291:537-543
51. de Groot PG, Willems C, Boers GH, et al: Endothelial cell dysfunction in homocystinura. Eur J Clin Invest 1983; 13:405-410
52. van den Berg M, Boers GH, Franken DG, et al: Hyperhomocysteinemia and endothelial cell dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25:176-181
53. kB dependent transcriptional activation of Nos2. Proc Am Assoc Phys 1998; 110:22-31
54. Stamler JS, Osborne JA, Jaraki O, et al: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91:308-318
55. Tsai J-C, Perrella MA, Yoshizumi M, et al: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91:6369-6373
56. Tsai JC, Wang H, Perrella MA, et al: Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97:146-153
57. D'Angelo A, Selhub J: Homocysteine and thrombotic disease. Blood 1997; 90:1-11
58. Rodgers GM, Conn MT: Homocysteine; an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75:895-901
59. Lentz SR, Sadler JE: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88:1906-1914
60. Nishinaga M, Ozawa T, Shimada K: Homocysteine, a thrombogenic agent, suppresses anticoagulant heparin sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92:1381-1386
61. Kuller LH, Evans RW: Homocysteine, vitamins and cardiovascular disease. Circulation 1998; 98:196-199
62. Brattstrom LE, Israelsson B, Jeppsson JO, et al: Folic acid, an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48:215-221
63. Saltzman E, Mason JB, Jacques PF, et al: B vitamin supplementation lowers homocysteine levels in heart disease (Abstract). Clin Res 1994; 42:172A
64. Boushey CJ, Berestord SAA, Omenn GS, et al: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA 1995; 274:1049-1057
65. Ueland PM, Refsum H: Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114:473-501
66. Ubbink JB, Vermaak WJH, van der Merwe A, et al: Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124:1927-1933
67. Malinow MR, Dwell PB, Hess DL, et al: Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998; 338:1009-1015
68. Boston AG, Shemin D, Pane D, et al: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49:147-152
69. Ali A, Mandeep MR, Lavie CJ, et al: Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and "normal" lipid levels. Am J Cardiol 1998; 82:1543-1545
70. Stampfer MJ, Malino MR: Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995; 332:328-329